Juan Alcaín

This study evaluates the effect of combining antiretroviral therapy (ART) with TIGIT or KLRG1 blockade in humanized mice, showing improved HIV-1 suppression and delayed viral rebound.

This study identifies the pre-TCR as a target for immunotherapy in T-ALL, showing that anti-pre-TCR antibodies inhibit leukemia-initiating cell activity and tumor progression in xenograft models.

This study identifies miR-15b/16-2 as tumor suppressors in T-cell acute lymphoblastic leukemia by showing their role in inhibiting proliferation and promoting apoptosis through repression of BCL-2 and CYCLIN D3.

This paper develops and validates a dual-targeting CAR-T cell therapy for T-ALL that targets CCR9 and CD1a, showing improved efficacy and safety compared to single-targeting approaches.

Combining dendritic cell stimulation with anti-TIGIT antibodies enhances memory NK cell cytotoxicity against HIV-1 infected CD4+ T cells in vitro and in vivo.